Transmission of human cytomegalovirus (CMV) via transfusion (TT‐CMV) may still occur
and remains a challenge in the treatment of immunocompromised CMV‐seronegative …

Background Allogeneic hematopoietic cell transplant recipients (allo-HCTRs) with positive
cytomegalovirus (CMV) serology may have false-positive results due to blood product …

Background CMV infection prevalence in kidney transplant recipients (KTR) is reported to be
high in the literature, reaching rates of over 80%. Objectives The primary endpoints were the …

Cytomegalovirus (CMV) reactivation post‐allogeneic hematopoietic cell transplantation
(post‐alloHCT) increases morbidity and mortality. We sought to determine the frequency of …

Reexploring cytomegalovirus serology in allogeneic hematopoietic cell transplantation
Page 1 QCO 370412 CURRENT OPINION Reexploring cytomegalovirus serology in …

Equivocal or borderline CMV IgG values in patients transfused with CMV-U components
may indicate passive rather than immune acquisition of IgG and should prompt a repeat …

Objectives To identify current UK practice with regards to provision of blood components for
cytomegalovirus (CMV)‐seronegative, potential, allogeneic stem cell recipients of …

BACKGROUND: Human cytomegalovirus (HCMV) infection is ubiquitous and successfully
reactivated in patients with immune dysfunction as in patient with multiple myeloma (MM) …

Background Accurate determination of recipient cytomegalovirus (CMV) serostatus before
allogeneic hematopoietic stem cell transplantation (HSCT) is critical, as it is the most …

We live in an era of increasing open access to academic journals, and many major funders
now insist on open access to published work arising from charitable or publicly funded work …